Sera Prognostics, Inc. Appoints Dr. Michael R. Foley as Chief Medical Officer
September 15, 2021 at 08:00 am EDT
Share
Sera Prognostics Inc. announced that Dr. Michael R. Foley has been appointed to the position of chief medical officer beginning in January 2022. Dr. Foley will lead all medical activities for Sera as the company executes its vision to be the Pregnancy Company™. He joins a group of talented clinical operations and medical professionals who support Sera’s collaborations with research teams across the globe. Dr. Michael Foley initially practiced Maternal-Fetal Medicine in private practice for more than 20 years and retires on December 31, 2021 from the role of Chairman of Obstetrics and Gynecology at the University of Arizona College of Medicine Phoenix/Banner Good Samaritan Regional Medical Center, where he served for nearly a decade and now is working with both the university and Sera in an orderly transition that is to be completed at year-end.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant motherâs risk of delivering spontaneously before 37 weeksâ gestation.
SERA PROGNOSTICS, INC. 
